Metastases to the central nervous system: Molecular basis and clinical considerations

被引:25
作者
Wanleenuwat, Pitchaya [1 ]
Iwanowski, Piotr [1 ]
机构
[1] Poznan Univ Med Sci, Dept Neurol, Przybyszewskiego 49, PL-60355 Poznan, Poland
关键词
Angiogenesis; Brain metabolism; Brain metastases; CNS metastases; Neuroinflammation; CELL LUNG-CANCER; ENDOTHELIAL GROWTH-FACTOR; BRAIN METASTASES; BREAST-CANCER; PROGNOSTIC-FACTORS; MATRIX METALLOPROTEINASES; KINASE INHIBITORS; TUMOR-CELLS; SURVIVAL; ANGIOGENESIS;
D O I
10.1016/j.jns.2020.116755
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Metastatic tumors are the most common malignancies of the central nervous system (CNS) in adults. CNS metastases are associated with unfavorable prognosis, high morbidity and mortality. Lung cancer is the most common source of brain metastases, followed by breast cancer and melanoma. Rising incidence is primarily due to improvements in systemic control of primary malignancies, prolonged survival and advances in cancer detection. Purpose: To provide an overview of the metastatic cascade and the role of angiogenesis, neuroinflammation, metabolic adaptations, and clinical details about brain metastases from different primary tumors. Methods: A review of the literature on brain metastases was conducted, focusing on the pathophysiology and clinical aspects of the disease. PubMed was used to search for relevant articles published from January 1975 through December 2019 using the keywords brain metabolism, brain metastasis, metastatic cascade, molecular mechanisms, incidence, risk factors, and prognosis. 146 articles met the criteria and were included in this review. Discussion: Some primary tumors have a higher tendency to metastasize to the CNS. Establishing a suitable metastatic microenvironment is important in maintaining tumor cell growth and survival. Magnetic resonance imaging (MRI) is a widely used tool for diagnosis and treatment monitoring. Available treatments include surgery, radiotherapy, stereotactic radiosurgery, chemotherapy, immunotherapy, and systemic targeted therapies. Conclusions: Prevention of metastases to the CNS remains a difficult challenge. Advances in screening of highrisk patients and future development of novel treatments may improve patient outcomes.
引用
收藏
页数:10
相关论文
共 145 条
[1]   Effective Treatment of Metastatic Melanoma by Combining MAPK and PI3K Signaling Pathway Inhibitors [J].
Aasen, Synnove Nymark ;
Parajuli, Himalaya ;
Tuyen Hoang ;
Feng, Zichao ;
Stokke, Krister ;
Wang, Jiwei ;
Roy, Kislay ;
Bjerkvig, Rolf ;
Knappskog, Stian ;
Thorsen, Frits .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (17)
[2]  
Agostinetto E, 2019, ANN ONCOL, V30
[3]   Brain metastasis as initial presentation of non-small cell lung cancer. [J].
Alshehri, Abdulrahman Ali ;
Monga, Manish ;
Wan, Sijin .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[4]   A phase II study of abemaciclib in patients (pts) with brain metastases (BM) secondary to HR+, HER2-metastatic breast cancer (MBC). [J].
Anders, Carey K. ;
Le Rhun, Emilie ;
Bachelot, Thomas Denis ;
Yardley, Denise A. ;
Awada, Ahmad ;
Conte, Pier Franco ;
Kabos, Peter ;
Bear, Melissa ;
Yang, Zhengyu ;
Chen, Yanyun ;
Tolaney, Sara M. .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[5]  
[Anonymous], [No title captured]
[6]  
[Anonymous], 2017, ONCOTARGET
[7]   Dramatic Response of Leptomeningeal Carcinomatosis to Nivolumab in PD-L1 Highly Expressive Non-small Cell Lung Cancer: A Case Report [J].
Arias Ron, David ;
Labandeira, Carmen M. ;
Areses Manrique, Maria Carmen ;
Sampedro Domarco, Paula ;
Abdulkader, Ihab ;
Garcia-Mata, Jesus ;
Rolfo, Christian ;
Gonzalez-Rivas, Diego ;
Luis Firvida, Jose .
FRONTIERS IN ONCOLOGY, 2019, 9
[8]   Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan Detroit cancer surveillance system [J].
Barnholtz-Sloan, JS ;
Sloan, AE ;
Davis, FG ;
Vigneau, FD ;
Lai, P ;
Sawaya, RE .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) :2865-2872
[9]  
Bartolotti M, 2012, EXPERT REV ANTICANC, V12, P1429, DOI [10.1586/ERA.12.121, 10.1586/era.12.121]
[10]   Brain metastases free survival differs between breast cancer subtypes [J].
Berghoff, A. ;
Bago-Horvath, Z. ;
De Vries, C. ;
Dubsky, P. ;
Pluschnig, U. ;
Rudas, M. ;
Rottenfusser, A. ;
Knauer, M. ;
Eiter, H. ;
Fitzal, F. ;
Dieckmann, K. ;
Mader, R. M. ;
Gnant, M. ;
Zielinski, C. C. ;
Steger, G. G. ;
Preusser, M. ;
Bartsch, R. .
BRITISH JOURNAL OF CANCER, 2012, 106 (03) :440-446